Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
The impact of s-irAEs on clinical outcomes may depend on the initial intervention required to manage the adverse event. s-irAEs were associated with worse outcomes when they initially required hospital/ED admission, corticosteroids, or other immunosuppression.
Authors
- Brian Dreyfus (ORCID: https://orcid.org/0000-0002-4241-9024)
- Douglas Buckner Johnson (ORCID: https://orcid.org/0000-0002-6390-773X)
- Charlotte Doran (ORCID: https://orcid.org/0009-0008-4824-377X)
- Jarushka Naidoo (ORCID: https://orcid.org/0000-0002-3470-8686)
- Zara Izadi (ORCID: https://orcid.org/0000-0002-1867-0905)
- Sari Hopson (ORCID: https://orcid.org/0000-0002-9835-0839)
- Shay Goldstein
- Lincy S. Lal (ORCID: https://orcid.org/0000-0002-9123-2434)
- Charmy Vyas
- Yan Zhang (ORCID: https://orcid.org/0000-0002-5027-6430)
- Yuexi Wang (ORCID: https://orcid.org/0000-0003-1749-0520)
- Trong Kim Le (ORCID: https://orcid.org/0000-0002-8808-4522)
Institutions
- Johns Hopkins University (US)
- Beaumont Hospital (IE)
- Bristol-Myers Squibb (United States) (US)
- Concert Pharmaceuticals (United States) (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/oncolo/oyae318
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Bristol-Myers Squibb